Results
A total of 18 patients were included in the analysis. The median follow-up was 21 months. No high-grade adverse events (CTCAE >2) or recto-urethral fistulae occurred. No statistically significant declines were observed in QoL outcomes (n = 11) on the EPIC bowel domain (P = 0.29), AUA symptom score (P = 0.77), or the SF-12 physical (P = 0.17) or SF-12 mental component summary (P = 0.77) questionnaires. At 6 months, patients who had undergone salvage therapy experienced a decline in EPIC sexual domain score (median of 38-24; P = 0.028) and urinary domain (median of 96-92; P = 0.074). Pad-free continence and erections sufficient for intercourse were preserved in 8/11 patients and 2/6 patients at 6 months, respectively. The mpMRI was clear in 11/13 patients, with two single out-field lesions (true-positive and false-positive, respectively). The median (interquartile range) nadir PSA was 0.39 (0.04-0.43) lg/L. Three and four patients experienced biochemical failure using the Phoenix and Stuttgart definitions of biochemical failure, respectively. Eight out of 10 of the patients were clear of any PCa on follow-up biopsy, whereas two patients had significant PCa on follow-up biopsy (International Society of Urological Pathology grade 5).
Introduction
Up to one-third of patients who undergo whole-gland radiotherapy (external beam radiotherapy, low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy as primary treatment for localized prostate cancer (PCa) experience radio-recurrent disease, with a high chance of developing clinically significant recurrent PCa [1] [2] [3] [4] . Current interventional salvage treatment options include radical prostatectomy, brachytherapy, whole-gland cryosurgery or high-intensity focused ultrasonography (HIFU) [5] . Surgical treatment of radio-recurrent PCa is challenging, with biochemical recurrence rates of between 28% and 93%, postintervention incontinence rates of between 5.4% and 67%, erectile dysfunction rates ranging from 23% to 100% and a significant incidence of high-grade adverse events, e.g. rectourethral fistula in 1-5.3% of patients [6, 7] . A systematic review including 10 series on robot-assisted radical prostatectomy for radio-recurrent PCa showed that biochemical failure occurred in 29% (56/193 patients) and urinary continence was preserved in 60% (119/197 patients) at a mean follow-up of 18.6 months, while the overall preserved potency rate was 26% in potent men (30/115 patients) [8] ; therefore, the majority of patients receive androgen deprivation therapy without curative intent [9, 10] .
Focal ablative therapy has been evaluated for localized radiorecurrent PCa, aiming to reduce treatment-related toxicity while achieving local oncological control. In a recent systematic review on focal salvage therapy for radio-recurrent PCa, the 5-year biochemical disease-free survival rate was 46.5-54.5% [6] . Feasibility trials have been performed with HIFU, cryosurgery, iodine-125 brachytherapy and HDR brachytherapy [6, 11] . For whole-gland salvage HIFU and cryosurgery, biochemical failure occurred in 3-79% of patients, and rates of preserved urinary continence and potency ranged from 10% to 93% and 15% to 56%, respectively [7] . For salvage brachytherapy, the biochemicalfree survival rate was 34-88% with grade 3-4 toxicity in 0-47% of patients [7] . Encouraging results regarding treatmentrelated toxicity of focal HIFU were reported by Ahmed et al. [12] ; however, other targeted focal therapy trials reported higher rates of recto-urethral fistula (5.5% [13] ), treatmentinduced erectile dysfunction (50% [14] ) and incontinence (25% [15] ).
Irreversible electroporation (IRE) is a novel focal therapy treatment which involves delivering high-voltage electrical pulses between needle electrodes [16] . The obtained direct electrical current destabilizes the targeted cellular membrane, inducing nanopores that cause irreversible permeability and subsequent cell death [16, 17] . Preclinical studies have shown that the ablative effect of IRE harbours tissue selectivity and is able to preserve blood vessel patency and spare nerves [18, 19] . The initial phase I-II trials with IRE for localized, treatment-na€ ıve PCa demonstrated the safety and feasibility of this technique, with limited treatment-related toxicity and good in-field oncological control [20] [21] [22] [23] . The feasibility of this technique and the interesting fundamental process of IRE may help to reduce treatment-related toxicity with salvage therapy; however, no studies have been published on focal IRE for radio-recurrent PCa to date. The aim of the present study was to demonstrate the feasibility of focal salvage IRE for localized, radio-recurrent PCa by acquiring patientreported quality-of-life (QoL), adverse event and early oncological control data.
Material and Methods

Study Design and Patients
Institutional review board approval was obtained to perform salvage IRE procedures, to acquire QoL data prospectively (HREC approval SVH 13/018) and to analyse retrospectively collected oncological data (HREC approval SVH 16/110). Patients with localized, radio-recurrent PCa (any Gleason sum score ≥6) without evidence of nodal or metastatic disease were offered salvage IRE in a single centre (St Vincent's Prostate Cancer Centre, Sydney, Australia) according to the consensus guidelines on salvage ablative therapy (Table 1 ) [24] . Written informed consent was obtained from all patients. Only patients with a minimum follow-up of 6 months were eligible for analysis. Adverse events, patientreported QoL and oncological control data were analysed.
Cancer Localization
Extensive systematic prostate biopsies were used to detect localized, radio-recurrent PCa and for treatment planning (median of 22 cores). Transperineal template-guided mapping biopsies were performed in 17/18 patients, while one patient received TRUS-guided template biopsies (n = 1, 21 cores; see Table 2 for specifications). Multiparametric MRI (mpMRI) was used to guide prostate biopsies. The mpMRI sequences were obtained and interpreted according to the Prostate Imaging Reporting and Data System (PI-RADS v1/v2) recommendations, and included T2-weighted imaging, dynamic contrast-enhanced imaging and diffusion-weighted imaging sequences. Specialized uro-radiologists reported the mpMRI results. Baseline whole-body restaging imaging (68-gallium prostate-specific membrane antigen [PSMA] positronemission tomography [PET]-CT scan, bone scan or choline PET-CT scan) was performed to exclude evidence of local or distant metastases.
Irreversible Electroporation Procedure
Salvage IRE was performed using the Nanoknife â system (Angiodynamics, Queensbury, NY, USA) by a single urologist (P.S.). Patients were placed in the lithotomy position after general anaesthesia. I.v. muscle paralysis and single-shot antibiotic prophylaxis were administered, followed by insertion of an indwelling urethral catheter. The needle electrodes (18-gauge) were placed through the perineum using TRUS guidance with a 5 9 5 mm brachytherapy template grid, surrounding the predefined treatment area with an extra safety margin of 5 mm (n = 1) and 10 mm (n = 17), based on biopsy and MRI evaluation. No Denonvilliers hydrodissection was performed. The number of electrodes and active tip length depended on the required ablation size based on the recurrent tumour volume. Ten test pulses were delivered with standard system settings (1 500 V/cm, pulse length of 70 ls [n = 7] or 90 ls [n = 11]). The pulse length was changed to comply with international standards after the first seven cases. When the obtained direct current of the test pulses reached the required current for the ablative effect of IRE (20-40 amperes between each electrode pair), the remaining 80 treatment pulses were administered. Patients were discharged within 24 h with oral antibiotics. The indwelling catheter was removed within 5 days.
Follow-Up
Safety Assessment
The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0) were used to report adverse event and safety data.
Patient-Reported Quality of Life Assessment
The Expanded Prostate Cancer Index Composite (EPIC) with specific urinary, sexual and bowel domains [25] , the AUA symptom score [26] and the 12-item short-form health survey (SF-12) physical and mental component summary [27] questionnaires were used to collect patient-reported QoL outcome data prospectively. Clinical data managers sent out and collected these questionnaires by mail at baseline, 6 weeks, and 3, 6 and 12 months.
Oncological Outcomes
T2-weighted MRI was performed 1 week after the IRE procedure to evaluate if the predefined treatment area was completely covered within the ablation zone. The follow-up mpMRI was performed at 6 months according to the recommendations of the Prostate Imaging Reporting and Data System (PI-RADS v1/v2) committee. The PI-RADS was used to score untreated prostate tissue and the ablation zone was scored with a dichotomous outcome: 'suspicious' or 'nonsuspicious' for residual in-field PCa. PSA was sequentially monitored. Follow-up PSMA PET-CT was performed in case of biochemical failure using the Phoenix definitions (PSA nadir + 2 lg/L). Our institutional protocol follows the recommendations of the consensus guidelines, with a systematic biopsy outcome at 12 months [24] . 
Analysis
Primary Outcomes
Rates of recto-urethral fistula and adverse events using CTCAE were recorded. Patient-reported QoL outcomes were reported for patients that consented to undergo QoL assessment and completed at least 6 months of follow-up.
Secondary Outcomes
Imaging-based oncological control was determined using the 6-month mpMRI. Suspicion for residual PCa was reported when the mpMRI results for out-field regions had a PI-RADS score of 3-5 and when in-field regions were deemed 'suspicious'. Biochemical failure was defined using two definitions: PSA nadir + 2 lg/L (Phoenix) and PSA nadir + 1.2 lg/L (Stuttgart [28] ). Any Gleason sum ≥6 (International Society of Urological Pathology [ISUP] grade 1-5) was considered as a positive biopsy outcome. PCa found inside or adjacent to the ablation zone was classified as in-field failure, while PCa found in untreated prostate tissue was classified as out-field failure.
Statistical Analysis
Wilcoxon's signed rank test was used to assess QoL differences over time in paired continuous variables (twotailed). SPSS v23 was used to perform all analyses, and P values <0.05 were taken to indicate statistical significance. Table 2 , including previous primary radiotherapy, pre-treatment MRI and biopsy results. On baseline imaging two patients underwent choline PET-CT only instead of the combination with mpMRI; one patient was ineligible to undergo mpMRI because he had a cardiac pacemaker and one patient refused restaging imaging.
Results
Baseline Characteristics
Peri-Operative Results
In all 18 patients a single ablative procedure was performed, targeting one lesion. In the majority of patients (16/18), four electrodes were used, with the other two procedures performed with five electrodes. IRE was performed in various (overlapping) segments of the prostate, including the anterior (n = 5), posterior (n = 13), apical (n = 5), base (n = 1) and apex-to-base segment (n = 12). All patients were discharged home within 24 h and the indwelling catheter was removed <5 days after treatment in 17/18 patients. Table 3 shows the peri-operative data.
Safety Outcomes
No peri-operative adverse events occurred. Five of the 18 patients described pain, urgency and mild haematuria postoperatively, not requiring any intervention (CTCAE grade 1). In two patients, grade 2 CTCAE adverse events were recorded postoperatively (n = 2). In one of these patients severe urinary continence post-IRE occurred as a result of urgency, which was mitigated at 6 weeks to urinary dribbling, requiring one pad per day. The other patient required 7 days of catheterization for postoperative urinary retention, most likely attributable to pre-existing LUTS. No high-grade adverse events occurred (CTCAE grade ≥3) and no patients developed recto-urethral fistula.
Quality of Life and Functional Outcomes
Eleven of the 18 patients (61%) consented to undergo QoL assessment and completed at least 6 months of follow-up. No statistically significant declines were observed in the QoL outcomes on the EPIC bowel domain (P = 0.29), SF-12 physical (P = 0.17) and mental component summary (P = 0.77) questionnaires at 6 months post-IRE. Baseline sexual function was low, as expected, and patients who had received salvage therapy experienced a significant further decline on the EPIC sexual domain (median score 38-24; P = 0.028) at 6 months post-treatment. Urinary domain QoL deteriorated marginally on the EPIC questionnaire (median score 96-92; P = 0.074) but not on the AUA symptom score (P = 0.77). Eight of the 11 patients that were pad-free continent at baseline remained pad-free continent at 6 months. Three patients required pads for urinary dribbling; this persisted up Figure 1 shows the median summary scores over time for QoL outcomes. Table 4 summarizes all outcomes by questionnaire.
Oncological Outcomes
At 6 months mpMRI was performed in 13 patients. Two patients declined mpMRI follow-up, two patients developed metastatic disease before the mpMRI endpoint (PCa and squamous cell skin cancer) and one patient is awaiting mpMRI. The mpMRI was clear in 11/13 patients, and in two patients the mpMRI identified a single out-field region of interest (true-positive and false-positive, respectively).
The median (IQR) nadir PSA was 0.39 (0.04-0.43) lg/L. Three and four patients experienced biochemical failure using the Phoenix and Stuttgart definitions of biochemical failure, respectively. The Phoenix definitions of biochemical failure identified three out of the four patients with recurrent or metastatic PCa, without false-positives. All four patients with recurrent or metastatic PCa were identified using the Stuttgart definitions, without false-positives. Follow-up PSMA PET-CT was performed in the three patients with biochemical failure (Phoenix), showing local recurrence, bone metastases and solitary pelvic lymph node disease, respectively. Salvage robotic lymph node dissection was performed on the patient with pelvic lymph node disease, achieving biochemical control.
Follow-up biopsies were performed in 10 patients, with a median of 20 cores. Nine patients underwent extensive transperineal template-guided mapping biopsies and one received transperineal-targeted biopsy. Three patients declined follow-up biopsies, two patients developed metastatic disease before biopsy endpoint (PCa and squamous cell skin cancer) and another three patients (median nadir PSA 0.16 lg/L) are awaiting follow-up biopsies. 8/10 of the patients were clear of any PCa on follow-up biopsy, whereas two patients had significant PCa on follow-up biopsy (both Gleason score 4 + 5 = 9/ISUP grade 5). One patient had in-field residual disease, which was treated with androgen deprivation therapy. The other patient had out-field residual disease re-treated with salvage IRE without any complications. The patient that had in-field residual disease was treated with a safety margin of 5 mm (1/1 patient), while no in-field failure occurred in patients treated with a safety margin of 10 mm (0/9 patients). Intention-to-treat oncological control was achieved in 8/12 patients. The oncological outcomes are summarized in Table 5 . Figure 2 shows the T2-weighted MRI scans after IRE for a patient previously treated with LDR brachytherapy.
Discussion
The main aim of the present study was to evaluate the initial feasibility and safety of salvage focal IRE for localized, radiorecurrent PCa. No high-grade adverse events or recto-urethral fistulae occurred during follow-up, suggesting salvage focal IRE is safe. Moreover, good intra-prostatic oncological control was found, with only two cases of intra-prostatic residual/ recurrent PCa. Our data also show the difficulty in truly excluding any metastatic disease at baseline because two patients developed metastatic disease <12 months after IRE. The use of 68-Ga PSMA PET CT scanning has been shown to detect PSMA-avid disease even at low PSA levels in patients with a biochemical recurrence after primary radiotherapy [29] . This may be used in a future trial to exclude metastatic disease at baseline. Following the consensus guidelines on focal salvage ablative therapy [24] , treatment planning and follow-up was performed using extensive template-mapping as no imaging technique has previously been validated for localizing (residual) radiorecurrent PCa. Our institutional analysis of primary IRE for localized PCa showed that in-field oncological control was superior in patients treated with an increased safety margin (10 mm) compared with patients treated with a limited safety margin (5 mm). This is in line with the findings of Le Nobin et al. [30] , who stated that a 9-mm safety margin should be respected. That finding seems to apply to the salvage cohort as well, although numbers are too small to draw any firm conclusions. All cases with residual or local/distant metastasis were identified using the Stuttgart definitions of biochemical failure, whereas the Phoenix definitions only missed one case. This too needs confirmation, however, in a larger cohort. Four patients without biochemical failure (median nadir PSA of 0.05 lg/L) did not receive follow-up biopsies due to refusal (n = 3) or ineligibility (metastatic squamous cell skin cancer) and another three patients with low nadir PSA are awaiting biopsies. This could have underestimated the biopsy-based oncological control and the failure to biopsy the entire cohort limits our biopsy-based outcomes. By contrast, we did not biopsy the patient who developed metastatic PCa before biopsy endpoint (PSA of 13 lg/L).
Salvage patients experienced a decline in sexual and urinary QoL, which is in line with other salvage trials [6] and is most likely attributable to the retreatment of already affected tissue as the baseline sexual function scores are similar to the decrease seen at 3 years after external beam radiotherapy and HDR brachytherapy [31] . The low baseline sexual function for patients previously treated with LDR brachytherapy, which are included in the QoL analysis, may be attributable to the older age (median 73 years) of these patients. The rates of urinary continence and erectile dysfunction are relatively high compared with other focal salvage trials [6, [12] [13] [14] 32] , but this is most likely the result of the 6-month evaluation point, low baseline sexual function and the relatively old age of our cohort (median 71 years). The largest series on focal salvage ablative therapy was performed with HIFU and included 150 men with a median follow-up of 35 months. Biochemical failure occurred in 51.3% (77/150 men) with a complication rate of 11.3% (including three cases of urethral fistula and one case of osteitis pubis). The QoL outcomes were limited because of missing data but were similar to the 12-month results of the present study; 87.5% (42/48 men) remained pad-free continent at 2 years and 58.3% remained potent (7/12 men). In the setting of focal IRE as primary treatment it has been shown that erectile function improved up to 12 months [23] . As with other PCa treatments, baseline age and sexual function may be significant determinants of developing erectile dysfunction after treatment [33] .
The outcomes of the present study are limited by the small sample size, short follow-up, heterogeneity in baseline imaging and single-centre retrospective nature of the study, which included the initial learning curve of the single surgeon. This confounds the conclusions that can be drawn. Moreover, patients had to cover medical expenses, which may have led to a bias towards higher treatment satisfaction. Our main aim, however, was to establish the feasibility and safety of IRE for radio-recurrent PCa, with evaluation of intraprostatic oncological control by extensive templatemapping biopsies before and after the IRE procedures. More robust long-term data are required and, based on these initial results, a prospective multicentre study (FIRE trial, ACTRN12617000806369) has been initiated (currently enrolling), evaluating focal IRE for localized, radio-recurrent PCa.
In conclusion, our short-term safety, QoL and oncological control data show that focal IRE is a feasible salvage option for localized radio-recurrent PCa. A prospective multicentre study has been initiated (FIRE trial) that will provide further insight into the ability of focal IRE to obtain oncological control with acceptable patient morbidity. Patients need to be counselled about the possibility of impaired short-term sexual and urinary QoL. 
